Vicplas Recommends No FY2026 Dividend as Medical Losses and Borrowings Rise

Vicplas International (SGX: 569) has recommended no dividend for the financial year ended 31 July 2026. In its results announced on 25 September, the board pointed to the group’s loss after tax. FY2025 also passed without a dividend, so investors looking for a payout restart will need to watch more than sales growth. The FY2026 figures have not been audited or reviewed. [S1, p. 17] [S1, p. 20] [S1, p. 22]

Sales grew, but the loss widened

Group revenue rose 10.0% to S$127.3 million in FY2026 from S$115.8 million a year earlier. Yet the loss after tax widened to S$5.1 million from S$2.4 million. Higher sales have not translated into group profit, the immediate obstacle cited by the board for its dividend decision. [S1, p. 3] [S1, p. 17]

The two businesses moved in different directions. The pipes and pipe fittings segment lifted revenue to S$48.2 million from S$38.6 million, while its segment result rose to S$10.2 million from S$6.7 million. Management attributed the stronger performance to higher sales and production volumes, including demand from Singapore construction projects and growth in Malaysia. These segment results are measured before corporate expenses, interest and tax. [S1, p. 11] [S1, p. 22]

Medical devices revenue edged up to S$79.1 million from S$77.2 million, but its segment loss deepened to S$8.7 million from S$2.6 million. Management said the Mexico plant incurred its first full year of operating costs while new projects were still ramping up; it also cited continuing costs at the Changzhou extension. More medical sales alone may therefore be insufficient: utilisation and costs need to improve for this larger business to support group earnings. [S1, p. 11] [S1, p. 21]

Cash improved, but investment still exceeded it

Net cash from operating activities increased to S$1.4 million from S$0.4 million. That is a welcome improvement, though the measure is after interest and tax paid and was still below the S$5.4 million of cash spent on property, plant and equipment. The difference was about S$4.0 million. It is a measure of this year’s cash funding gap, not a forecast of future spending. [S1, p. 7]

Bank borrowings rose to S$35.3 million at 31 July 2026 from S$27.2 million a year earlier. Of the latest balance, S$28.2 million was repayable within one year or on demand, against S$5.9 million of cash and cash equivalents. The filing says the increase in bank borrowings mainly funded medical devices working capital and capital expenditure. Those balances make cash generation and borrowing terms relevant to any eventual dividend return. [S1, p. 4] [S1, p. 14] [S1, p. 16] [S1, p. 20]

What would change the dividend picture?

The no-dividend decision is consistent with a wider group loss and cash investment exceeding operating cash inflow. The stronger pipes business helps, but it has not offset the medical devices loss. For the next results, the useful tests are whether Mexico’s rising production reduces that loss, whether operating cash covers investment more comfortably, and whether bank borrowings stop climbing. Those outcomes would provide firmer evidence of payout capacity than revenue growth by itself. [S1, p. 7] [S1, p. 11] [S1, p. 14] [S1, p. 17] [S1, p. 21]